Acceleron Pharma Stock Price, News & Analysis (NASDAQ:XLRN)

$38.71 1.74 (4.71 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$36.97
Today's Range$36.70 - $38.85
52-Week Range$23.07 - $40.35
Volume284,820 shs
Average Volume392,826 shs
Market Capitalization$1.54342 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:XLRN
  • CUSIP: N/A
  • Web: www.acceleronpharma.com
Debt:
  • Current Ratio: 21.63%
  • Quick Ratio: 21.63%
Sales & Book Value:
  • Annual Sales: $27.77 million
  • Price / Sales: 63.06
  • Book Value: $7.93 per share
  • Price / Book: 4.88
Profitability:
  • Trailing EPS: ($2.59)
  • Net Income: ($57,010,000.00)
  • Net Margins: -759.34%
  • Return on Equity: -40.70%
  • Return on Assets: -37.44%
Misc:
  • Employees: 121
  • Outstanding Shares: 45,240,000
 
Frequently Asked Questions for Acceleron Pharma (NASDAQ:XLRN)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.02. The biopharmaceutical company earned $3 million during the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.55) EPS. View Acceleron Pharma's Earnings History.

When will Acceleron Pharma make its next earnings announcement?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Acceleron Pharma.

Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?

17 brokerages have issued 1-year price targets for Acceleron Pharma's stock. Their forecasts range from $20.00 to $63.00. On average, they anticipate Acceleron Pharma's share price to reach $45.07 in the next year. View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

  • 1. Cann analysts commented, "Acceleron Pharma announced today that The Lancet Oncology has published results from the phase II study of Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS). Acceleron reported that the article, entitled Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2 dose-finding study with long-term extension study" is now available online and will be published in a future print issue of The Lancet Oncology. The journal also published online a companion Comment article, Defeating anaemia in myelodysplastic syndromes: another step forward," by Valeria Santini, M.D., Associate Professor of Hematology at the University of Florence Medical School in Florence, Italy." (9/5/2017)
  • 2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)
  • 3. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)

Are investors shorting Acceleron Pharma?

Acceleron Pharma saw a increase in short interest during the month of October. As of October 13th, there was short interest totalling 3,647,870 shares, an increase of 29.3% from the September 29th total of 2,821,173 shares. Based on an average daily volume of 420,662 shares, the short-interest ratio is currently 8.7 days. Approximately 10.4% of the shares of the stock are short sold.

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:

  • Francois E. Nader M.D., Independent Chairman of the Board (Age 60)
  • Habib J. Dable, President, Chief Executive Officer, Director (Age 47)
  • Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer (Age 60)
  • Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer (Age 61)
  • Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer (Age 57)
  • John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary (Age 45)
  • Jean M. George, Independent Director (Age 59)
  • George S. Golumbeski Ph.D., Independent Director (Age 59)
  • Terrence C. Kearney, Independent Director (Age 62)
  • Tom Maniatis Ph.D., Independent Director (Age 73)

Who owns Acceleron Pharma stock?

Acceleron Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (3.57%), Westfield Capital Management Co. LP (3.41%), Eagle Asset Management Inc. (2.75%), Pictet Asset Management Ltd. (1.63%), Brown Advisory Inc. (1.02%) and First Manhattan Co. (0.84%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Who sold Acceleron Pharma stock? Who is selling Acceleron Pharma stock?

Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Pictet Asset Management Ltd., TD Asset Management Inc., Eagle Asset Management Inc., Platinum Investment Management Ltd., Cornerstone Capital Management Holdings LLC., Verde Servicos Internacionais S.A. and California State Teachers Retirement System. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Insider Buying and Selling for Acceleron Pharma.

Who bought Acceleron Pharma stock? Who is buying Acceleron Pharma stock?

Acceleron Pharma's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Artisan Partners Limited Partnership, JPMorgan Chase & Co., Prudential Financial Inc., New York State Common Retirement Fund, Alyeska Investment Group L.P., Point72 Asset Management L.P. and Iguana Healthcare Management LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy Acceleron Pharma stock?

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of Acceleron Pharma stock can currently be purchased for approximately $38.71.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $1.54342 billion and generates $27.77 million in revenue each year. The biopharmaceutical company earns ($57,010,000.00) in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 121 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200.


MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $45.07 (16.42% upside)
Consensus Price Target History for Acceleron Pharma (NASDAQ:XLRN)
Price Target History for Acceleron Pharma (NASDAQ:XLRN)
Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
11/14/2017Credit Suisse GroupSet Price TargetBuy$35.00 -> $51.00N/AView Rating Details
11/7/2017HC WainwrightBoost Price TargetBuy -> Buy$57.00 -> $62.00N/AView Rating Details
11/2/2017Royal Bank Of CanadaReiterated RatingHoldN/AView Rating Details
9/20/2017Barclays PLCBoost Price TargetOverweight$42.00 -> $50.00HighView Rating Details
9/5/2017CannReiterated RatingHoldLowView Rating Details
8/4/2017Citigroup Inc.Boost Price TargetBuy$44.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingBuy$40.00MediumView Rating Details
6/14/2017InstinetReiterated RatingBuy$58.00LowView Rating Details
6/13/2017FBR & CoSet Price TargetBuy$63.00HighView Rating Details
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 -> $42.00HighView Rating Details
6/13/2017CIBCDowngradeOutperform -> Market PerformLowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Initiated CoverageSell -> Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
3/14/2017J P Morgan Chase & CoInitiated CoverageNeutral -> Neutral$33.00HighView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Acceleron Pharma (NASDAQ:XLRN)
Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Earnings History by Quarter for Acceleron Pharma (NASDAQ XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/7/2017Q3 2017($0.67)($0.65)$3.52 million$3.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.65)($0.77)$3.69 million$3.10 millionViewListenView Earnings Details
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
2017 EPS Consensus Estimate: ($2.51)
2018 EPS Consensus Estimate: ($2.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.62)($0.51)($0.57)
Q2 20173($0.69)($0.62)($0.66)
Q3 20173($0.71)($0.59)($0.64)
Q4 20173($0.75)($0.57)($0.63)
Q1 20181($0.57)($0.57)($0.57)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Acceleron Pharma (NASDAQ XLRN)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 75.85%
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Insider Trades by Quarter for Acceleron Pharma (NASDAQ XLRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Corp /De/ CelgeneMajor ShareholderBuy745,592$37.00$27,586,904.00View SEC Filing  
9/13/2017John D QuiselSVPSell5,113$38.42$196,441.46View SEC Filing  
9/12/2017Christopher RovaldiSVPSell14,000$38.41$537,740.00View SEC Filing  
9/12/2017Kevin F MclaughlinCFOSell16,000$38.41$614,560.00View SEC Filing  
9/12/2017Matthew L ShermanEVPSell18,400$38.41$706,744.00View SEC Filing  
8/8/2017Ravindra KumarSVPSell13,065$35.41$462,631.65View SEC Filing  
7/5/2017Kevin F MclaughlinCFOSell34,400$32.00$1,100,800.00View SEC Filing  
7/5/2017Matthew L ShermanEVPSell16,000$32.00$512,000.00View SEC Filing  
7/5/2017Ravindra KumarSVPSell937$32.00$29,984.00View SEC Filing  
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.00View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.00View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.00View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.88View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.12View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.60View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.32View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Acceleron Pharma (NASDAQ:XLRN)
Latest Headlines for Acceleron Pharma (NASDAQ XLRN)
Source:
DateHeadline
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific SessionsAcceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
finance.yahoo.com - November 16 at 9:31 AM
Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuireAcceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
finance.yahoo.com - November 16 at 9:31 AM
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195
finance.yahoo.com - November 16 at 9:31 AM
Acceleron Pharma Inc. (XLRN) PT Set at $51.00 by Credit Suisse GroupAcceleron Pharma Inc. (XLRN) PT Set at $51.00 by Credit Suisse Group
www.americanbankingnews.com - November 14 at 10:52 AM
$3.37 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter$3.37 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter
www.americanbankingnews.com - November 14 at 4:50 AM
FY2017 Earnings Forecast for Acceleron Pharma Inc. (XLRN) Issued By Oppenheimer HoldingsFY2017 Earnings Forecast for Acceleron Pharma Inc. (XLRN) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 12:26 PM
FY2017 EPS Estimates for Acceleron Pharma Inc. (XLRN) Decreased by AnalystFY2017 EPS Estimates for Acceleron Pharma Inc. (XLRN) Decreased by Analyst
www.americanbankingnews.com - November 9 at 6:20 AM
Edited Transcript of XLRN earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of XLRN earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 7 at 9:09 PM
Acceleron Pharma Inc. (XLRN) Issues  Earnings Results, Misses Expectations By $0.02 EPSAcceleron Pharma Inc. (XLRN) Issues Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - November 7 at 4:20 PM
Notable Tuesday Option Activity: XLRN, SHLD, ZNotable Tuesday Option Activity: XLRN, SHLD, Z
www.thestreet.com - November 7 at 4:08 PM
The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your BetsThe Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your Bets
seekingalpha.com - November 7 at 4:08 PM
Acceleron Pharma Reports Third Quarter 2017 Operational and Financial ResultsAcceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
finance.yahoo.com - November 7 at 4:08 PM
Acceleron reports 3Q lossAcceleron reports 3Q loss
finance.yahoo.com - November 7 at 4:08 PM
HC Wainwright Boosts Acceleron Pharma Inc. (XLRN) Price Target to $62.00HC Wainwright Boosts Acceleron Pharma Inc. (XLRN) Price Target to $62.00
www.americanbankingnews.com - November 7 at 3:52 PM
Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : November 6, 2017Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : November 6, 2017
finance.yahoo.com - November 6 at 3:21 PM
Acceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by BrokeragesAcceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 1:58 PM
Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : November 3, 2017Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : November 3, 2017
finance.yahoo.com - November 5 at 8:22 AM
Acceleron Pharmas (XLRN) "Hold" Rating Reiterated at Royal Bank Of CanadaAcceleron Pharma's (XLRN) "Hold" Rating Reiterated at Royal Bank Of Canada
www.americanbankingnews.com - November 2 at 2:44 PM
Acceleron Pharma (XLRN) to Present Clinical Presentations at ASHAcceleron Pharma (XLRN) to Present Clinical Presentations at ASH
www.streetinsider.com - November 2 at 11:46 AM
Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and ExpositionAcceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - November 1 at 11:02 AM
Acceleron Pharma (XLRN) vs. Its Peers Financial AnalysisAcceleron Pharma (XLRN) vs. Its Peers Financial Analysis
www.americanbankingnews.com - October 28 at 9:12 PM
Acceleron Pharma Inc. (XLRN) Short Interest UpdateAcceleron Pharma Inc. (XLRN) Short Interest Update
www.americanbankingnews.com - October 28 at 1:50 AM
Head-To-Head Comparison: Acceleron Pharma (XLRN) vs. Its PeersHead-To-Head Comparison: Acceleron Pharma (XLRN) vs. Its Peers
www.americanbankingnews.com - October 27 at 11:26 PM
Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - October 27 at 7:47 AM
Acceleron Pharma Stock Sees Short Interest Expand By 29.3%Acceleron Pharma Stock Sees Short Interest Expand By 29.3%
www.thestreet.com - October 26 at 5:35 AM
Edited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMTEdited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMT
finance.yahoo.com - October 26 at 5:35 AM
Zacks: Analysts Expect Acceleron Pharma Inc. (XLRN) Will Post Quarterly Sales of $3.08 MillionZacks: Analysts Expect Acceleron Pharma Inc. (XLRN) Will Post Quarterly Sales of $3.08 Million
www.americanbankingnews.com - October 25 at 10:00 AM
Acceleron Pharma Inc. (XLRN) Scheduled to Post Earnings on WednesdayAcceleron Pharma Inc. (XLRN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:04 AM
Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : October 23, 2017Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : October 23, 2017
finance.yahoo.com - October 23 at 9:15 AM
Options Traders Expect Huge Moves in Acceleron Pharma (XLRN) StockOptions Traders Expect Huge Moves in Acceleron Pharma (XLRN) Stock
finance.yahoo.com - October 18 at 10:50 AM
Acceleron Pharma Inc. (XLRN) Coverage Initiated at HC WainwrightAcceleron Pharma Inc. (XLRN) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - October 15 at 7:56 AM
Acceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by AnalystsAcceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 12 at 3:16 PM
Oppenheimer Holdings Weighs in on Acceleron Pharma Inc.s Q3 2017 Earnings (XLRN)Oppenheimer Holdings Weighs in on Acceleron Pharma Inc.'s Q3 2017 Earnings (XLRN)
www.americanbankingnews.com - October 9 at 1:02 AM
Acceleron Pharma Inc. (XLRN) Downgraded to Sell at ValuEngineAcceleron Pharma Inc. (XLRN) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - October 7 at 9:58 PM
Acceleron Announces Closing Of Underwriters Option To Purchase Additional SharesAcceleron Announces Closing Of Underwriters' Option To Purchase Additional Shares
www.thestreet.com - October 6 at 4:43 AM
$3.35 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter$3.35 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter
www.americanbankingnews.com - October 6 at 2:32 AM
Acceleron Announces Closing of Underwriters’ Option to Purchase Additional SharesAcceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 5 at 1:37 PM
Insider Buying: Acceleron Pharma Inc. (XLRN) Major Shareholder Buys 745,592 Shares of StockInsider Buying: Acceleron Pharma Inc. (XLRN) Major Shareholder Buys 745,592 Shares of Stock
www.americanbankingnews.com - September 25 at 7:14 PM
Analysts Set Expectations for Acceleron Pharma Inc.s Q3 2017 Earnings (XLRN)Analysts Set Expectations for Acceleron Pharma Inc.'s Q3 2017 Earnings (XLRN)
www.americanbankingnews.com - September 25 at 1:16 AM
Acceleron Pharma Inc. (XLRN) PT Raised to $50.00 at Barclays PLCAcceleron Pharma Inc. (XLRN) PT Raised to $50.00 at Barclays PLC
www.americanbankingnews.com - September 23 at 9:02 PM
Acceleron Announces Pricing of Public Offering of Common StockAcceleron Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 23 at 12:32 PM
What Is Acceleron Pharma Inc’s (XLRN) Share Price Doing?What Is Acceleron Pharma Inc’s (XLRN) Share Price Doing?
finance.yahoo.com - September 23 at 12:32 PM
Oppenheimer Holdings, Inc. Reiterates "Hold" Rating for Acceleron Pharma Inc. (XLRN)Oppenheimer Holdings, Inc. Reiterates "Hold" Rating for Acceleron Pharma Inc. (XLRN)
www.americanbankingnews.com - September 20 at 3:52 PM
Acceleron Pharma (XLRN) Plans $150M Offering of Common StockAcceleron Pharma (XLRN) Plans $150M Offering of Common Stock
www.streetinsider.com - September 20 at 11:20 AM
Acceleron to Develop Sotatercept in Pulmonary Arterial HypertensionAcceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
finance.yahoo.com - September 19 at 9:52 AM
Acceleron Pharma Inc. (XLRN) Given Consensus Recommendation of "Buy" by AnalystsAcceleron Pharma Inc. (XLRN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 17 at 10:36 AM
Acceleron Pharma Inc. (XLRN) SVP Sells $196,441.46 in StockAcceleron Pharma Inc. (XLRN) SVP Sells $196,441.46 in Stock
www.americanbankingnews.com - September 14 at 11:36 PM
Royal Bank Of Canada Begins Coverage on Acceleron Pharma Inc. (XLRN)Royal Bank Of Canada Begins Coverage on Acceleron Pharma Inc. (XLRN)
www.americanbankingnews.com - September 14 at 11:06 PM
Acceleron Pharma Inc. (XLRN) EVP Sells $706,744.00 in StockAcceleron Pharma Inc. (XLRN) EVP Sells $706,744.00 in Stock
www.americanbankingnews.com - September 14 at 10:52 PM
Acceleron Pharma Inc. (XLRN) CFO Kevin F. Mclaughlin Sells 16,000 SharesAcceleron Pharma Inc. (XLRN) CFO Kevin F. Mclaughlin Sells 16,000 Shares
www.americanbankingnews.com - September 14 at 10:52 PM

Social Media

Financials

Chart

Acceleron Pharma (NASDAQ XLRN) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.